News

DINAMIQS obtains ExcellGene’s HEKExpress® and HEK2Express® cell line technologies for viral vector GMP manufacturing

DINAMIQS, a Siegfried company, today announced a licensing agreement with ExcellGene to access its HEKExpress® and HEK2Express® suspension cell line technologies. These will be used in GMP manufacturing of recombinant Adeno-associated virus (rAAV) and Lentivirus (rLV) vectors for both in-vivo and ex-vivo gene therapies. Eduard Ayuso, Chief Technical Officer at DINAMIQS:...

read more

Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the formation of a Scientific Advisory Board (SAB) for its radiopharmaceuticals,...

read more

Mabylon AG Initiates Phase I Clinical Trial of Lead Compound MY006 for the Treatment of Peanut Allergy

Schlieren/Zurich, Switzerland, December 11, 2025- Mabylon AG, a leader in the high- throughput discovery, engineering, and development of human-derived antibodies for the treatment of allergies, neurodegenerative diseases, and inflammation, today announced that the first healthy volunteer has been dosed in the first-in-human clinical trial evaluating MY006, a novel tri-specific monoclonal...

read more